Moleculin Biotech, Inc. SEC filings MBRX
Moleculin Biotech, Inc. has 838 filings in SEC EDGAR's recent list, going back to Dec 4, 2015. Its latest annual report, Form 10-K, was filed on Mar 18, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Aug 13, 2026, covering the quarter ended Jun 30, 2026. The most recent current report (Form 8-K) was filed on Nov 4, 2026 (regulation fd disclosure). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| EFFECT | Filing | Jul 31, 2026 | — |
| DRS | Filing | Jul 15, 2026 | — |
| EFFECT | Filing | Apr 14, 2026 | — |
| CORRESP | Letter to the SEC | Apr 10, 2026 | — |
| UPLOAD | Letter from the SEC | Apr 2, 2026 | — |
| EFFECT | Filing | Jan 6, 2026 | — |
| CORRESP | Letter to the SEC | Jan 2, 2026 | — |
| UPLOAD | Letter from the SEC | Jan 2, 2026 | — |
| PRER14A | Form prer14a | Dec 22, 2025 | — |
| EFFECT | Filing | Sep 30, 2025 | — |
| CORRESP | Letter to the SEC | Sep 29, 2025 | — |
| UPLOAD | Letter from the SEC | Sep 24, 2025 | — |
| EFFECT | Filing | Jun 20, 2025 | — |
| CORRESP | Letter to the SEC | Jun 17, 2025 | — |
| CORRESP | Letter to the SEC | Jun 17, 2025 | — |
| CORRESP | Letter to the SEC | Jun 16, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2025 | — |
| CORRESP | Letter to the SEC | Jun 11, 2025 | — |
| UPLOAD | Letter from the SEC | Jun 10, 2025 | — |
| CORRESP | Letter to the SEC | Jun 3, 2025 | — |
| CORRESP | Letter to the SEC | Jun 3, 2025 | — |
| DRS | Filing | May 23, 2025 | — |
| EFFECT | Filing | Apr 7, 2025 | — |
| CORRESP | Letter to the SEC | Apr 4, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 4, 2025 | — |
| RW | Form rw | Feb 24, 2025 | — |
| EFFECT | Filing | Dec 9, 2024 | — |
| EFFECT | Filing | Aug 15, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| CORRESP | Letter to the SEC | Aug 15, 2024 | — |
| UPLOAD | Letter from the SEC | Jul 26, 2024 | — |
| EFFECT | Filing | Jul 1, 2024 | — |
| CORRESP | Letter to the SEC | Jun 27, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 13, 2024 | — |
| EFFECT | Filing | Feb 12, 2024 | — |
| CORRESP | Letter to the SEC | Feb 9, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 9, 2024 | — |
| EFFECT | Filing | Jun 11, 2021 | — |
| CORRESP | Letter to the SEC | Jun 9, 2021 | — |
| UPLOAD | Letter from the SEC | Jun 4, 2021 | — |
| EFFECT | Filing | Apr 9, 2020 | — |
| CORRESP | Letter to the SEC | Apr 7, 2020 | — |
| RW | Filing | Jan 21, 2020 | — |
| CORRESP | Letter to the SEC | Jan 7, 2020 | — |
| UPLOAD | Letter from the SEC | Jan 6, 2020 | — |
| NT 10-Q | Filing | Aug 14, 2019 | Jun 30, 2019 |
| PRER14A | Pre 14a | Apr 12, 2019 | — |
| EFFECT | Filing | Oct 26, 2018 | — |
| CORRESP | Letter to the SEC | Oct 25, 2018 | — |
| CORRESP | Letter to the SEC | Oct 25, 2018 | — |
| CORRESP | Letter to the SEC | Oct 24, 2018 | — |
| UPLOAD | Letter from the SEC | Oct 23, 2018 | — |
| EFFECT | Filing | Jul 23, 2018 | — |
| CORRESP | Letter to the SEC | Jul 19, 2018 | — |
| UPLOAD | Letter from the SEC | Jul 19, 2018 | — |
| CT ORDER | Filing | Jul 13, 2018 | — |
| EFFECT | Filing | May 24, 2018 | — |
| CORRESP | Letter to the SEC | May 23, 2018 | — |
| EFFECT | Filing | Oct 23, 2017 | — |
| EFFECT | Filing | Aug 21, 2017 | — |
| CORRESP | Letter to the SEC | Aug 18, 2017 | — |
| CORRESP | Letter to the SEC | Aug 11, 2017 | — |
| UPLOAD | Letter from the SEC | Aug 1, 2017 | — |
| NT 10-K | Filing | Apr 3, 2017 | Dec 31, 2016 |
| EFFECT | Filing | Feb 8, 2017 | — |
| CORRESP | Letter to the SEC | Feb 8, 2017 | — |
| CORRESP | Letter to the SEC | Feb 8, 2017 | — |
| CORRESP | Letter to the SEC | Feb 8, 2017 | — |
| CORRESP | Letter to the SEC | Jan 18, 2017 | — |
| UPLOAD | Letter from the SEC | Dec 19, 2016 | — |
| NT 10-Q | Filing | Nov 15, 2016 | Sep 30, 2016 |
| CERTNAS | Auto-generated paper document | Jun 1, 2016 | — |
| D | Filing | May 16, 2016 | — |
| EFFECT | Filing | May 2, 2016 | — |
| 8-A12B | Filing | Apr 28, 2016 | — |
| CORRESP | Letter to the SEC | Apr 28, 2016 | — |
| CORRESP | Letter to the SEC | Apr 28, 2016 | — |
| CORRESP | Letter to the SEC | Apr 15, 2016 | — |
| UPLOAD | Letter from the SEC | Apr 13, 2016 | — |
| CORRESP | Letter to the SEC | Mar 21, 2016 | — |
| UPLOAD | Letter from the SEC | Mar 4, 2016 | — |
| CORRESP | Letter to the SEC | Feb 1, 2016 | — |
| UPLOAD | Letter from the SEC | Jan 4, 2016 | — |
| DRS | Filing | Dec 4, 2015 | — |
Showing 84 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- MBRX (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Houston, TX
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1659617
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.